DE60138717D1 - Peptidomimetika als protease inhibitoren - Google Patents
Peptidomimetika als protease inhibitorenInfo
- Publication number
- DE60138717D1 DE60138717D1 DE60138717T DE60138717T DE60138717D1 DE 60138717 D1 DE60138717 D1 DE 60138717D1 DE 60138717 T DE60138717 T DE 60138717T DE 60138717 T DE60138717 T DE 60138717T DE 60138717 D1 DE60138717 D1 DE 60138717D1
- Authority
- DE
- Germany
- Prior art keywords
- peptidomimetics
- protease inhibitors
- protease
- inhibitors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22939800P | 2000-08-31 | 2000-08-31 | |
US27764101P | 2001-03-21 | 2001-03-21 | |
PCT/US2001/026008 WO2002018369A2 (en) | 2000-08-31 | 2001-08-31 | Peptidomimetic protease inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60138717D1 true DE60138717D1 (de) | 2009-06-25 |
Family
ID=26923261
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60143233T Expired - Lifetime DE60143233D1 (de) | 2000-08-31 | 2001-08-31 | Verfahren zur Herstellung chiraler Bicycloprolinate als Intermediate zur Herstellung von Inhibitoren der peptidomimetischen Protease |
DE60138717T Expired - Lifetime DE60138717D1 (de) | 2000-08-31 | 2001-08-31 | Peptidomimetika als protease inhibitoren |
DE20122915U Expired - Lifetime DE20122915U1 (de) | 2000-08-31 | 2001-08-31 | Peptidomimetika als Protease Inhibitoren |
DE201212000015 Pending DE122012000015I1 (de) | 2000-08-31 | 2012-03-19 | Peptidomimetika als protease inhibitoren. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60143233T Expired - Lifetime DE60143233D1 (de) | 2000-08-31 | 2001-08-31 | Verfahren zur Herstellung chiraler Bicycloprolinate als Intermediate zur Herstellung von Inhibitoren der peptidomimetischen Protease |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE20122915U Expired - Lifetime DE20122915U1 (de) | 2000-08-31 | 2001-08-31 | Peptidomimetika als Protease Inhibitoren |
DE201212000015 Pending DE122012000015I1 (de) | 2000-08-31 | 2012-03-19 | Peptidomimetika als protease inhibitoren. |
Country Status (37)
Country | Link |
---|---|
US (5) | US7820671B2 (de) |
EP (9) | EP2368877B1 (de) |
JP (4) | JP4689938B2 (de) |
KR (10) | KR20080104384A (de) |
CN (7) | CN101696232A (de) |
AR (1) | AR030591A1 (de) |
AT (2) | ATE483686T1 (de) |
AU (2) | AU2001288318B2 (de) |
BR (1) | BR0113666A (de) |
CA (2) | CA2419607C (de) |
CL (1) | CL2010000330A1 (de) |
CY (2) | CY1109216T1 (de) |
CZ (1) | CZ2003595A3 (de) |
DE (4) | DE60143233D1 (de) |
DK (2) | DK1320540T5 (de) |
DZ (1) | DZ3438A1 (de) |
EA (2) | EA017556B1 (de) |
EC (2) | ECSP034493A (de) |
ES (4) | ES2325481T3 (de) |
HK (3) | HK1163061A1 (de) |
HR (1) | HRP20030139B8 (de) |
HU (1) | HUP0300855A3 (de) |
IL (6) | IL154671A0 (de) |
LU (1) | LU91960I2 (de) |
MX (1) | MXPA03001780A (de) |
NO (4) | NO329929B1 (de) |
NZ (2) | NZ541302A (de) |
PE (1) | PE20020474A1 (de) |
PL (1) | PL211019B1 (de) |
PT (1) | PT1320540E (de) |
SI (1) | SI1320540T1 (de) |
SK (1) | SK2492003A3 (de) |
SV (1) | SV2003000617A (de) |
TW (6) | TWI359145B (de) |
UA (2) | UA81600C2 (de) |
WO (1) | WO2002018369A2 (de) |
ZA (1) | ZA200301641B (de) |
Families Citing this family (237)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA001915B1 (ru) * | 1996-10-18 | 2001-10-22 | Вертекс Фармасьютикалз Инкорпорейтед | Ингибиторы серин-протеаз, в частности ns3 протеазы вируса гепатита c (hvc) |
US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
ES2240446T3 (es) * | 2000-04-03 | 2005-10-16 | Vertex Pharma | Inhibidores de serina proteasas, particularmente la proteasa ns3 del virus de la hepatitis c. |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
CN1315862C (zh) | 2000-05-26 | 2007-05-16 | 艾登尼科斯(开曼)有限公司 | 处理黄病毒和瘟病毒的方法和组合物 |
HUP0303358A3 (en) | 2000-07-21 | 2005-10-28 | Schering Corp | Novel peptides as ns3-serine protease inhibitors of hepatitis c virus and pharmaceutical compositions containing them |
KR100939155B1 (ko) | 2000-07-21 | 2010-01-28 | 쉐링 코포레이션 | C형 간염 바이러스의 ns3-세린 프로테아제 억제제로서의신규한 펩티드 |
US7244721B2 (en) | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
SV2003000617A (es) * | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
GB2368339B (en) | 2000-10-26 | 2002-09-18 | Yissum Res Dev Co | Complex incorporating a plurality of antioxidants |
CA2462163A1 (en) * | 2001-10-24 | 2003-05-01 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system |
US7119072B2 (en) | 2002-01-30 | 2006-10-10 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis C virus |
US7091184B2 (en) | 2002-02-01 | 2006-08-15 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
US6642204B2 (en) | 2002-02-01 | 2003-11-04 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
AU2003223602B8 (en) * | 2002-04-11 | 2010-05-27 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis C virus NS3-NS4 protease |
ES2361011T3 (es) * | 2002-05-20 | 2011-06-13 | Bristol-Myers Squibb Company | Inhibidores del virus de la hepatitis c. |
TW200500374A (en) | 2002-06-28 | 2005-01-01 | Idenlx Cayman Ltd | 2' and 3' -nucleoside produrgs for treating flavivridae infections |
US7608600B2 (en) | 2002-06-28 | 2009-10-27 | Idenix Pharmaceuticals, Inc. | Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections |
WO2004026896A2 (en) * | 2002-09-23 | 2004-04-01 | Medivir Ab | Hcv ns-3 serine protease inhibitors |
US20050075279A1 (en) | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
DE60331367D1 (de) | 2002-12-30 | 2010-04-01 | Angiotech Int Ag | Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung |
AU2011203054B2 (en) * | 2003-04-11 | 2012-04-26 | Vertex Pharmaceuticals, Incorporated | Inhibitors of Serine Proteases, Particularly HCV NS3-NS4A Protease |
CN100453553C (zh) * | 2003-04-11 | 2009-01-21 | 沃泰克斯药物股份有限公司 | 丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂 |
TW200510391A (en) * | 2003-04-11 | 2005-03-16 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
DE602004010137T2 (de) | 2003-05-21 | 2008-09-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verbindungen als hepatitis c inhibitoren |
SI2604620T1 (sl) | 2003-05-30 | 2016-10-28 | Gilead Pharmasset LLC c/o Gilead Sciences, Inc. | Modificirani fluorirani nukleozidni analogi |
CN102020700A (zh) | 2003-07-18 | 2011-04-20 | 沃泰克斯药物股份有限公司 | 丝氨酸蛋白酶抑制剂、特别是hcv ns3-ns4a蛋白酶抑制剂 |
TW201127828A (en) | 2003-09-05 | 2011-08-16 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
US20050120398A1 (en) * | 2003-09-12 | 2005-06-02 | Vertex Pharmaceuticals Incorporated | Animal model for HCV infection |
WO2005028502A1 (en) | 2003-09-18 | 2005-03-31 | Vertex Pharmaceuticals, Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
CN1906208B (zh) * | 2003-10-10 | 2011-03-30 | 沃泰克斯药物股份有限公司 | 丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂 |
RU2006115558A (ru) | 2003-10-10 | 2007-11-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Ингибиторы сериновых протеаз, особенно hcv ns3-ns4a протеазы |
EP1944042A1 (de) | 2003-10-27 | 2008-07-16 | Vertex Pharmceuticals Incorporated | Kombinationen für die HCV-Behandlung |
JP4890254B2 (ja) | 2003-10-27 | 2012-03-07 | バーテックス ファーマシューティカルズ インコーポレイテッド | Hcvns3−ns4aプロテアーゼ耐性突然変異体 |
DE602004018363D1 (de) * | 2003-10-27 | 2009-01-22 | Vertex Pharma | Kombinationen für die hcv-behandlung |
WO2005043118A2 (en) | 2003-10-27 | 2005-05-12 | Vertex Pharmaceuticals Incorporated | Drug discovery method |
US7485625B2 (en) * | 2003-12-11 | 2009-02-03 | Schering Corporation | Inhibitors of hepatitis C virus NS3/NS4a serine protease |
ES2358333T3 (es) | 2004-01-21 | 2011-05-09 | Boehringer Ingelheim International Gmbh | Péptidos macrocíclicos con acción contra el virus de la hepatitis c. |
CA2554999A1 (en) * | 2004-02-04 | 2005-08-25 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
JP4745327B2 (ja) | 2004-02-27 | 2011-08-10 | シェーリング コーポレイション | C型肝炎ウイルスns3プロテアーゼのインヒビター |
TW200529822A (en) * | 2004-02-27 | 2005-09-16 | Schering Corp | Novel ketoamides with cyclic p4's as inhibitors of ns3 serine protease of hepatitis c virus |
ES2328589T3 (es) | 2004-02-27 | 2009-11-16 | Schering Corporation | Compuestos de la prolina 3,4(ciclopentil) fusionados como inhibidores de la proteasa serina ns3 del virus de la hepatitis c. |
KR101316137B1 (ko) * | 2004-02-27 | 2013-10-10 | 머크 샤프 앤드 돔 코포레이션 | C형 간염 바이러스 ns3 세린 프로테아제의 억제제로서의황 화합물 |
WO2005123076A2 (en) * | 2004-06-08 | 2005-12-29 | Vertex Pharmaceuticals, Inc. | Pharmaceutical compositions |
CA2573346C (en) | 2004-07-20 | 2011-09-20 | Boehringer Ingelheim International Gmbh | Hepatitis c inhibitor peptide analogs |
UY29016A1 (es) | 2004-07-20 | 2006-02-24 | Boehringer Ingelheim Int | Analogos de dipeptidos inhibidores de la hepatitis c |
KR20070061570A (ko) * | 2004-10-01 | 2007-06-13 | 버텍스 파마슈티칼스 인코포레이티드 | Hcv ns3-ns4a 프로테아제 저해 |
TW201424733A (zh) * | 2004-10-29 | 2014-07-01 | Vertex Pharma | 劑量型式 |
CA2602175C (en) | 2005-03-21 | 2012-11-27 | Applera Corporation | Alpha ketoamide compounds as cysteine protease inhibitors |
US20070015803A1 (en) * | 2005-04-12 | 2007-01-18 | Romark Laboratories L.C. | Methods for treating diseases through interruption of protein maturation, compounds that inhibit the function of molecular chaperones such as protein disulfide isomerases or interfere with glycosylation, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents |
KR20080016597A (ko) | 2005-05-13 | 2008-02-21 | 바이로켐 파마 인코포레이티드 | 플라비바이러스 감염의 예방 또는 치료용 화합물 및 그의예방 또는 치료 방법 |
US20060276404A1 (en) * | 2005-06-02 | 2006-12-07 | Anima Ghosal | Medicaments and methods combining a HCV protease inhibitor and an AKR competitor |
BRPI0610737A2 (pt) | 2005-06-02 | 2010-07-20 | Schering Corp | formulações farmacêuticas e métodos de tratamento usando as mesmas |
NZ563361A (en) | 2005-06-02 | 2011-02-25 | Schering Corp | HCV protease inhibitors in combination with food |
WO2006130553A2 (en) * | 2005-06-02 | 2006-12-07 | Schering Corporation | Hcv protease inhibitors |
US7608592B2 (en) | 2005-06-30 | 2009-10-27 | Virobay, Inc. | HCV inhibitors |
AU2006274861B2 (en) | 2005-07-29 | 2012-11-08 | Medivir Ab | Macrocyclic inhibitors of hepatitis C virus |
PE20070210A1 (es) | 2005-07-29 | 2007-04-16 | Tibotec Pharm Ltd | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
EP1919899B1 (de) | 2005-07-29 | 2011-01-19 | Tibotec Pharmaceuticals | Makrocyclische inhibitoren des hepatitis-c-virus |
RU2437886C2 (ru) | 2005-07-29 | 2011-12-27 | Тиботек Фармасьютикалз Лтд. | Макроциклические ингибиторы вируса гепатита с |
PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
EP1913015B1 (de) | 2005-07-29 | 2013-12-11 | Janssen R&D Ireland | Makrozyklische hemmer des hepatitis-c-virus |
JO2768B1 (en) | 2005-07-29 | 2014-03-15 | تيبوتيك فارماسيوتيكالز ليمتد | Large cyclic inhibitors of hepatitis C virus |
CN101282978B (zh) | 2005-07-29 | 2012-07-11 | 泰博特克药品有限公司 | 丙型肝炎病毒的大环抑制剂 |
EP2402331A1 (de) | 2005-08-02 | 2012-01-04 | Vertex Pharmaceuticals Incorporated | Serinprotease-Hemmer |
US8399615B2 (en) | 2005-08-19 | 2013-03-19 | Vertex Pharmaceuticals Incorporated | Processes and intermediates |
PT1934179E (pt) * | 2005-08-19 | 2010-07-12 | Vertex Pharma | PROCESSOS E INTERMEDIáRIOS |
US7964624B1 (en) | 2005-08-26 | 2011-06-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases |
AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
NZ568324A (en) | 2005-11-11 | 2012-01-12 | Vertex Pharma | Hepatitis C virus variants |
US7705138B2 (en) | 2005-11-11 | 2010-04-27 | Vertex Pharmaceuticals Incorporated | Hepatitis C virus variants |
JP3975226B2 (ja) * | 2006-01-11 | 2007-09-12 | 生化学工業株式会社 | シクロアルキルカルボニルアミノ酸誘導体及びその製造方法 |
CA2636765C (en) * | 2006-01-11 | 2014-03-18 | Seikagaku Corporation | Cycloalkylcarbonylamino acid ester derivative and process for producing the same |
JP4047365B2 (ja) * | 2006-01-11 | 2008-02-13 | 生化学工業株式会社 | シクロアルカンカルボキサミド誘導体及びその製造方法 |
WO2007083620A1 (ja) * | 2006-01-20 | 2007-07-26 | Kaneka Corporation | β-アミノ-α-ヒドロキシ酸アミド誘導体の製造法 |
EP1991229A2 (de) | 2006-02-27 | 2008-11-19 | Vertex Pharmaceuticals Incorporated | Kokristalle und pharmazeutische zusammensetzungen damit |
JP5646814B2 (ja) | 2006-03-06 | 2014-12-24 | アッヴィ・インコーポレイテッド | Hcvを治療するためのリトナビルの組成物及び使用方法 |
NZ571280A (en) * | 2006-03-16 | 2011-10-28 | Vertex Pharma | Deuterated hepatitis C protease inhibitors |
JP5313124B2 (ja) * | 2006-03-16 | 2013-10-09 | バーテックス ファーマシューティカルズ インコーポレイテッド | 立体的化合物を製造するための方法および中間体 |
AU2007226984B2 (en) | 2006-03-20 | 2013-02-21 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions |
EP1998759A2 (de) * | 2006-03-23 | 2008-12-10 | Schering Corporation | Kombinationen aus hcv-protease-hemmer(n) und cyp3a4-hemmer(n) sowie damit zusammenhängende behandlungsverfahren |
WO2007120595A2 (en) * | 2006-04-11 | 2007-10-25 | Novartis Ag | Amines for the treatment of hcv |
MX2008013119A (es) | 2006-04-11 | 2008-10-21 | Novartis Ag | Inhibidores de hcv/vih y sus usos. |
AU2007253819B2 (en) | 2006-05-23 | 2011-02-17 | Irm Llc | Compounds and compositions as channel activating protease inhibitors |
DE102006059317A1 (de) | 2006-07-04 | 2008-01-10 | Evonik Degussa Gmbh | Verfahren zur Herstellung von β-Amino-α-hydroxy-carbonsäureamiden |
EP1886685A1 (de) | 2006-08-11 | 2008-02-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methoden, Verwendungen und Zusammensetzungen zur Modulation der Replikation von HCV durch Aktivierung oder Hemmung des Farnesoid X Rezeptors |
US20120220520A1 (en) * | 2006-10-17 | 2012-08-30 | Van T Klooster Gerben Albert Eleutherius | Bioavailable combinations for hcv treatment |
PL2104674T3 (pl) | 2006-11-15 | 2013-12-31 | Vertex Pharmaceuticals Canada Incorporated | Analogi tiofenu do leczenia lub zapobiegania zakażeniom flawiwirusowym |
WO2008059046A1 (en) | 2006-11-17 | 2008-05-22 | Tibotec Pharmaceuticals Ltd. | Macrocyclic inhibitors of hepatitis c virus |
JP2010512317A (ja) * | 2006-12-07 | 2010-04-22 | シェーリング コーポレイション | pH感受性マトリクス処方物 |
WO2008074035A1 (en) * | 2006-12-27 | 2008-06-19 | Abbott Laboratories | Hcv protease inhibitors and uses thereof |
WO2008095058A1 (en) * | 2007-02-01 | 2008-08-07 | Taigen Biotechnology Co. Ltd. | Hcv protease inhibitors |
CN101641349A (zh) | 2007-02-08 | 2010-02-03 | 泰博特克药品有限公司 | 嘧啶取代的大环抑制剂 |
EA016327B1 (ru) | 2007-02-09 | 2012-04-30 | Айрм Ллк | Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы |
NZ579295A (en) | 2007-02-27 | 2012-03-30 | Vertex Pharma | Inhibitors of serine proteases |
AU2008219607B2 (en) * | 2007-02-27 | 2013-09-12 | Vertex Pharmaceuticals Incorporated | Co-crystals and pharmaceutical compositions comprising the same |
US20080255038A1 (en) * | 2007-04-11 | 2008-10-16 | Samuel Earl Hopkins | Pharmaceutical compositions |
CA2686051A1 (en) | 2007-05-04 | 2008-11-13 | Vertex Pharmaceuticals Incorporated | Combination therapy for the treatment of hcv infection |
NZ583652A (en) * | 2007-08-03 | 2012-06-29 | Biotron Ltd | Hepatitis c antiviral compositions and methods |
ATE530546T1 (de) * | 2007-08-30 | 2011-11-15 | Vertex Pharma | Kokristalle und pharmazeutische zusammensetzungen damit |
AU2008301981A1 (en) | 2007-09-14 | 2009-03-26 | Merck Sharp & Dohme Corp. | Method of treating hepatitis C patients |
US20090082366A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched telaprevir |
WO2009047264A1 (en) | 2007-10-10 | 2009-04-16 | Novartis Ag | Spiropyrrolidines and their use against hcv and hiv infection |
US8106059B2 (en) | 2007-10-24 | 2012-01-31 | Virobay, Inc. | Substituted pyrazines that inhibit protease cathepsin S and HCV replication |
WO2009055335A2 (en) * | 2007-10-25 | 2009-04-30 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
BRPI0821836A2 (pt) | 2007-12-24 | 2015-06-16 | Tibotec Pharm Ltd | Indóis macrocíclicos como inibidores do vírus da hepatite c |
DE102008009761A1 (de) | 2008-02-19 | 2009-08-27 | Bayer Materialscience Ag | Verfahren zur Herstellung von Isocyanaten |
EP2101173A1 (de) | 2008-03-14 | 2009-09-16 | Vivalis | In-vitro-Verfahren zur Bestimmung, ob ein gegen ein Zielprotein aktiver Arzneimittelkandidat aktiv gegen eine Variante des besagten Proteins ist |
CN101580535B (zh) * | 2008-05-16 | 2012-10-03 | 太景生物科技股份有限公司 | 丙型肝炎病毒蛋白酶抑制剂 |
KR20110048509A (ko) | 2008-06-24 | 2011-05-11 | 코덱시스, 인코포레이티드 | 실질적으로 입체이성질체적으로 순수한 융합 이환식 프롤린 화합물의 제조를 위한 생체촉매 공정 |
US8569337B2 (en) | 2008-07-23 | 2013-10-29 | Vertex Pharmaceuticals Incorporated | Tri-cyclic pyrazolopyridine kinase inhibitors |
WO2010014744A1 (en) * | 2008-07-29 | 2010-02-04 | The Scripps Research Institute | Inhibitors of hepatitis c virus infection |
US8188137B2 (en) | 2008-08-15 | 2012-05-29 | Avila Therapeutics, Inc. | HCV protease inhibitors and uses thereof |
US8865756B2 (en) | 2008-12-03 | 2014-10-21 | Presidio Pharmaceuticals, Inc. | Inhibitors of HCV NS5A |
WO2010065674A1 (en) | 2008-12-03 | 2010-06-10 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
GB0900914D0 (en) | 2009-01-20 | 2009-03-04 | Angeletti P Ist Richerche Bio | Antiviral agents |
WO2010093843A2 (en) | 2009-02-12 | 2010-08-19 | Vertex Pharmaceuticals Incorporated | Hcv combination therapies |
MX2011010132A (es) | 2009-03-27 | 2011-10-14 | Presidio Pharmaceuticals Inc | Inhibidores de anillo fusionado de hepatitis c. |
US8512690B2 (en) | 2009-04-10 | 2013-08-20 | Novartis Ag | Derivatised proline containing peptide compounds as protease inhibitors |
US20110182850A1 (en) | 2009-04-10 | 2011-07-28 | Trixi Brandl | Organic compounds and their uses |
US20100324059A1 (en) | 2009-06-23 | 2010-12-23 | Gilead Sciences, Inc. | Pharmaceutical compositions useful for treating hcv |
HUE030402T2 (en) | 2009-09-15 | 2017-05-29 | Taigen Biotechnology Co Ltd | HCV protease inhibitors |
TWI404269B (zh) * | 2009-09-18 | 2013-08-01 | Advanced Connectek Inc | High speed plug connector |
UA108211C2 (uk) | 2009-11-04 | 2015-04-10 | Янссен Рід Айрленд | Бензімідазолімідазольні похідні |
EP2504329A1 (de) | 2009-11-25 | 2012-10-03 | Vertex Pharmaceuticals Incorporated | 5-alkynyl-thiophen-2-carbonsäurederivate und ihre verwendung zur behandlung oder prävention von flavivirus-infektionen |
MX2012006877A (es) * | 2009-12-18 | 2012-08-31 | Idenix Pharmaceuticals Inc | Inhibidores de virus de hepatitis c de arileno o heteroarileno 5, 5 - fusionado. |
MX2012007420A (es) | 2009-12-24 | 2012-07-23 | Vertex Pharma | Analogos para el tratamiento o prevencion de infecciones de flavivirus. |
US20110178107A1 (en) * | 2010-01-20 | 2011-07-21 | Taigen Biotechnology Co., Ltd. | Hcv protease inhibitors |
US8653025B2 (en) | 2010-01-27 | 2014-02-18 | AB Pharma Ltd. | Polyheterocyclic compounds highly potent as HCV inhibitors |
JP2013518124A (ja) | 2010-01-29 | 2013-05-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | C型肝炎ウイルス感染の処置のための治療法 |
WO2011112516A1 (en) | 2010-03-08 | 2011-09-15 | Ico Therapeutics Inc. | Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides |
JP2013522377A (ja) | 2010-03-24 | 2013-06-13 | バーテックス ファーマシューティカルズ インコーポレイテッド | フラビウイルス感染を処置または予防するためのアナログ |
MX2012010918A (es) | 2010-03-24 | 2013-01-18 | Vertex Pharma | Analogos para el tratamiento o prevencion de infecciones por flavivirus. |
EP2550262A1 (de) | 2010-03-24 | 2013-01-30 | Vertex Pharmaceuticals Incorporated | Analoga zur behandlung oder vorbeugung von flavivirus-infektionen |
EP2550268A1 (de) | 2010-03-24 | 2013-01-30 | Vertex Pharmaceuticals Incorporated | Analoga zur behandlung oder vorbeugung von flavivirus-infektionen |
US8680071B2 (en) | 2010-04-01 | 2014-03-25 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
CA2800509A1 (en) | 2010-05-24 | 2011-12-01 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
KR20130082137A (ko) | 2010-06-03 | 2013-07-18 | 버텍스 파마슈티칼스 인코포레이티드 | 방법 및 중간체 |
WO2011156545A1 (en) | 2010-06-09 | 2011-12-15 | Vertex Pharmaceuticals Incorporated | Viral dynamic model for hcv combination therapy |
WO2011159826A2 (en) | 2010-06-15 | 2011-12-22 | Vertex Pharmaceuticals Incorporated | Hcv ns5b protease mutants |
WO2012006070A1 (en) | 2010-06-28 | 2012-01-12 | Vertex Pharmaceuticals Incorporated | Compounds and methods for the treatment or prevention of flavivirus infections |
MX2012014918A (es) | 2010-06-28 | 2013-04-08 | Vertex Pharma | Compuestos y metodos para tratamiento o prevencion de infecciones por flavivirus. |
JP2013531011A (ja) | 2010-06-28 | 2013-08-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | フラビウイルス感染の処置または予防のための化合物および方法 |
EP2593105A1 (de) | 2010-07-14 | 2013-05-22 | Vertex Pharmaceuticals Incorporated | Wohlschmeckende pharmazeutische zusammensetzung mit vx-950 |
WO2012020036A1 (en) | 2010-08-13 | 2012-02-16 | F. Hoffmann-La Roche Ag | Hepatitis c virus inhibitors |
MX2013001869A (es) | 2010-08-17 | 2013-06-28 | Vertex Pharma | Compuestos y metodos para el tratamiento o prevencion de infecciones virales por flaviviridae. |
CN103209987B (zh) | 2010-09-22 | 2017-06-06 | 艾丽奥斯生物制药有限公司 | 取代的核苷酸类似物 |
AU2011311880B2 (en) | 2010-10-08 | 2014-07-24 | Novartis Ag | Vitamin E formulations of sulfamide NS3 inhibitors |
CA2815416A1 (en) | 2010-10-21 | 2012-04-26 | Vertex Pharmaceuticals Incorporated | Biomarkers for hcv infected patients |
NZ609564A (en) | 2010-10-26 | 2015-06-26 | Presidio Pharmaceuticals Inc | Inhibitors of hepatitis c virus |
WO2012109646A1 (en) | 2011-02-11 | 2012-08-16 | Vertex Pharmaceuticals Incorporated | Treatment of hcv in hiv infection patients |
WO2012107589A1 (en) | 2011-02-11 | 2012-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment and prevention of hcv infections |
WO2012123298A1 (en) | 2011-03-11 | 2012-09-20 | F. Hoffmann-La Roche Ag | Antiviral compounds |
JP2014514295A (ja) | 2011-03-31 | 2014-06-19 | アイディニックス ファーマシューティカルズ インコーポレイテッド | ウイルス感染の治療のための化合物および薬学的組成物 |
WO2012151319A1 (en) | 2011-05-02 | 2012-11-08 | Virobay, Inc. | Cathepsin inhibitors for the treatment of bone cancer and bone cancer pain |
EP2707347A1 (de) | 2011-05-13 | 2014-03-19 | Vertex Pharmaceuticals Inc. | Verfahren und zwischenprodukte |
CA2857705A1 (en) | 2011-06-16 | 2012-12-20 | AB Pharma Ltd. | Macrocyclic heterocyclic compounds for inhibiting hepatitis c virus and preparation and use thereof |
CN103732242A (zh) | 2011-06-23 | 2014-04-16 | 迪格纳生物技术公司 | 用与IFN-α2b组合的IFN-α5在患者群体中治疗慢性丙型肝炎 |
US20120328565A1 (en) | 2011-06-24 | 2012-12-27 | Brinkman John A | Antiviral compounds |
AR087345A1 (es) | 2011-07-26 | 2014-03-19 | Vertex Pharma | Metodos para la preparacion de compuestos de tiofeno |
WO2013016499A1 (en) | 2011-07-26 | 2013-01-31 | Vertex Pharmaceuticals Incorporated | Methods for preparation of thiophene compounds |
JP2014526474A (ja) | 2011-09-12 | 2014-10-06 | アイディニックス ファーマシューティカルズ インコーポレイテッド | ウイルス感染の治療のための化合物および薬学的組成物 |
CA2850003C (en) | 2011-09-27 | 2020-01-07 | Kansas State University Research Foundation | Broad-spectrum antivirals against 3c or 3c-like proteases of picornavirus-like supercluster: picornaviruses, caliciviruses and coronaviruses |
JP5808496B2 (ja) | 2011-10-10 | 2015-11-10 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 抗ウイルス化合物 |
HUE034857T2 (en) | 2011-10-14 | 2018-03-28 | Bristol Myers Squibb Co | Substituted tetrahydroisoquinoline compounds are inhibitors of factor XIA |
ES2579832T3 (es) | 2011-10-14 | 2016-08-17 | Bristol-Myers Squibb Company | Compuestos de tetrahidroisoquinolina sustituida como inhibidores del factor XIa |
ES2699226T3 (es) | 2011-10-14 | 2019-02-08 | Bristol Myers Squibb Co | Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIa |
DE202012013117U1 (de) | 2011-10-21 | 2015-01-16 | Abbvie Inc. | Kombinationsbehandlung (z.B. mit ABT-072 oder ABT-333 von DAAs zur Verwendung in der Behandlung von HCV) |
DE112012003510T5 (de) | 2011-10-21 | 2015-03-19 | Abbvie Inc. | Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
US8492386B2 (en) * | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
KR20140104030A (ko) | 2011-12-16 | 2014-08-27 | 에프. 호프만-라 로슈 아게 | Hcv ns5a의 억제제 |
MX350809B (es) | 2011-12-20 | 2017-09-20 | Riboscience Llc | Derivados nucleósidos con sustitución 2',4'-difluoro-2'-metilo como inhibidores de la replicación del arn del vhc. |
MX350810B (es) | 2011-12-20 | 2017-09-20 | Riboscience Llc | Derivados de los nucleosidos sustituidos en 4 '-azido, 3 '-fluoro como inhibidores de la replicacion del rna del vhc. |
CN104203940B (zh) | 2011-12-28 | 2017-01-18 | 爱尔兰詹森科学公司 | 作为hcv抑制剂的杂双环衍生物 |
WO2013116339A1 (en) | 2012-01-31 | 2013-08-08 | Vertex Pharmaceuticals Incorporated | High potency formulations of vx-950 |
ITMI20120192A1 (it) | 2012-02-13 | 2013-08-14 | Dipharma Francis Srl | Procedimento per la preparazione di un inibitore delle proteasi virali e suoi intermedi |
CA2864669A1 (en) * | 2012-02-16 | 2013-08-22 | Rqx Pharmaceuticals, Inc. | Linear peptide antibiotics |
CN104185624B (zh) | 2012-02-24 | 2016-10-12 | 弗·哈夫曼-拉罗切有限公司 | 抗病毒化合物 |
ITMI20120359A1 (it) | 2012-03-07 | 2013-09-08 | Dipharma Francis Srl | Procedimento per la preparazione di intermedi utili nella preparazione di un inibitore delle proteasi virali |
WO2013136265A1 (en) | 2012-03-13 | 2013-09-19 | Dipharma Francis S.R.L. | Synthesis of an intermediate of an antiviral compound |
ITMI20120391A1 (it) * | 2012-03-13 | 2013-09-14 | Dipharma Francis Srl | Procedimento per la sintesi di un intermedio ciclopropilammidico utile nella preparazione di un inibitore delle proteasi virali |
CN104321333A (zh) | 2012-03-21 | 2015-01-28 | 沃泰克斯药物股份有限公司 | 硫代氨基磷酸酯核苷酸前药的固体形式 |
NZ630805A (en) | 2012-03-22 | 2016-01-29 | Alios Biopharma Inc | Pharmaceutical combinations comprising a thionucleotide analog |
EP2844249A4 (de) | 2012-05-02 | 2016-03-09 | Univ Kansas State | Makrocyclische und peptidomimetische verbindungen als viruzide gegen 3c- oder 3c-like-proteasen von picornaviren, caliciviren und coronaviren |
ITMI20120800A1 (it) * | 2012-05-10 | 2013-11-11 | Dipharma Francis Srl | Procedimento per la preparazione di un intermedio utile nella preparazione di un inibitore delle proteasi virali |
CN103450066B (zh) * | 2012-05-30 | 2017-03-15 | 博瑞生物医药(苏州)股份有限公司 | 特拉匹韦中间体的制备方法 |
AR091192A1 (es) | 2012-05-30 | 2015-01-21 | Chemo Iberica Sa | Procedimiento multicomponente para la preparacion de compuestos biciclicos |
US20140010783A1 (en) | 2012-07-06 | 2014-01-09 | Hoffmann-La Roche Inc. | Antiviral compounds |
WO2014015217A1 (en) | 2012-07-19 | 2014-01-23 | Vertex Pharmaceuticals Incorporated | Biomarkers for hcv infected patients |
WO2014033667A1 (en) | 2012-08-30 | 2014-03-06 | Ranbaxy Laboratories Limited | Process for the preparation of telaprevir |
WO2014045263A2 (en) * | 2012-09-24 | 2014-03-27 | Dr. Reddy's Laboratories Limited | Process for preparation of intermediates of telaprevir |
EP2906552B1 (de) | 2012-10-12 | 2017-11-22 | Bristol-Myers Squibb Company | Guanidinsubstituierte tetrahydroisochinoline als factor xia inhibitoren |
EP2906541B1 (de) | 2012-10-12 | 2017-11-22 | Bristol-Myers Squibb Company | Guanidin- und aminsubstituierte tetrahydroisochinoline als factor xia inhibitoren |
TR201807316T4 (tr) | 2012-10-12 | 2018-06-21 | Squibb Bristol Myers Co | Bir faktör XIa inhibitörünün kristalli formları. |
EP2912047B1 (de) | 2012-10-29 | 2016-08-24 | Cipla Limited | Antivirale phosphonatanaloga und verfahren zur herstellung davon |
ITMI20122036A1 (it) | 2012-11-29 | 2014-05-30 | Dipharma Francis Srl | Sintesi di un intermedio di un composto antivirale |
WO2014096374A1 (en) | 2012-12-21 | 2014-06-26 | Sandoz Ag | Process for the synthesis of pyrrolidines and pyrroles |
BR112015017414A2 (pt) | 2013-01-23 | 2017-07-11 | Hoffmann La Roche | derivados de triazol antivirais |
CN103113288B (zh) * | 2013-02-04 | 2015-05-20 | 苏州永健生物医药有限公司 | 一种八氢环戊烯并[c]吡咯羧酸衍生物的合成方法 |
US20150065439A1 (en) | 2013-02-28 | 2015-03-05 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions |
KR20150114566A (ko) | 2013-03-05 | 2015-10-12 | 에프. 호프만-라 로슈 아게 | 항바이러스 화합물 |
ES2712699T3 (es) | 2013-03-25 | 2019-05-14 | Bristol Myers Squibb Co | Tetrahidroisoquinolinas que contienen azoles sustituidos como inhibidores del factor XIa |
ITMI20130706A1 (it) | 2013-04-30 | 2014-10-31 | Dipharma Francis Srl | Procedimento per la preparazione di un inibitore delle proteasi virali e suoi intermedi |
US20180200280A1 (en) | 2013-05-16 | 2018-07-19 | Riboscience Llc | 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication |
NZ714927A (en) | 2013-05-16 | 2020-09-25 | Riboscience Llc | 4’-fluoro-2’-methyl substituted nucleoside derivatives |
WO2014193663A1 (en) | 2013-05-16 | 2014-12-04 | Riboscience Llc | 4'-azido, 3'-deoxy-3'-fluoro substituted nucleoside derivatives |
CN104163851B (zh) * | 2013-05-20 | 2019-03-05 | 湘北威尔曼制药股份有限公司 | 氟代的α-羰基类HCV NS3/4A丝氨酸蛋白酶抑制剂 |
CN103288671B (zh) * | 2013-06-20 | 2014-10-29 | 上海步越化工科技有限公司 | 一种(3s)-3-氨基-n-环丙基-2-羟基己酰胺盐酸盐的合成方法 |
WO2014203224A1 (en) | 2013-06-21 | 2014-12-24 | Ranbaxy Laboratories Limited | Process for the preparation of telaprevir and its intermediates |
WO2014203208A1 (en) | 2013-06-21 | 2014-12-24 | Ranbaxy Laboratories Limited | Process for the preparation of telaprevir and intermediates thereof |
CN104292146B (zh) * | 2013-06-24 | 2017-04-26 | 上海医药工业研究院 | 特拉匹韦中间体及其制备方法 |
CN104558106B (zh) * | 2013-10-19 | 2019-12-10 | 广东东阳光药业有限公司 | 一种治疗丙肝药物的制备方法 |
CN104610272B (zh) * | 2013-11-05 | 2017-03-29 | 上海唐润医药科技有限公司 | 环状黄酮或异黄酮类化合物及其用途 |
EP2899207A1 (de) | 2014-01-28 | 2015-07-29 | Amikana.Biologics | Neues Verfahren zum Testen von HCV-Proteasehemmung |
NO2760821T3 (de) | 2014-01-31 | 2018-03-10 | ||
MY190429A (en) | 2014-01-31 | 2022-04-21 | Bristol Myers Squibb Co | Macrocycles with hetrocyclic p2' groups as factor xia inhibitors |
CN104926712B (zh) * | 2014-03-20 | 2018-03-23 | 上海医药工业研究院 | 合成特拉匹韦的中间体及其制备方法 |
CN104926831A (zh) * | 2014-03-20 | 2015-09-23 | 上海医药工业研究院 | 合成特拉匹韦的中间体及其制备方法 |
AU2014400642B2 (en) | 2014-07-07 | 2018-01-04 | Halliburton Energy Services, Inc. | Downhole tools comprising aqueous-degradable sealing elements |
JP6526796B2 (ja) | 2014-09-04 | 2019-06-05 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Fxia阻害剤であるジアミドマクロ環 |
US9453018B2 (en) | 2014-10-01 | 2016-09-27 | Bristol-Myers Squibb Company | Pyrimidinones as factor XIa inhibitors |
CN108699105A (zh) | 2016-03-04 | 2018-10-23 | 豪夫迈·罗氏有限公司 | 作为htra1抑制剂的新型二氟酮酰胺衍生物 |
JP2019513698A (ja) | 2016-03-04 | 2019-05-30 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Htra1阻害剤としての新規なトリフルオロメチルプロパンアミド誘導体 |
CN109689063A (zh) | 2016-04-28 | 2019-04-26 | 埃默里大学 | 含有炔烃的核苷酸和核苷治疗组合物及其相关用途 |
EP3472149B1 (de) | 2016-06-21 | 2023-08-30 | Orion Ophthalmology LLC | Heterocyclische prolinamidderivate |
WO2017222914A1 (en) | 2016-06-21 | 2017-12-28 | Inception 4, Inc. | Carbocyclic prolinamide derivatives |
JP7076438B2 (ja) | 2016-06-21 | 2022-05-27 | オリオン・オフサルモロジー・エルエルシー | 脂肪族プロリンアミド誘導体 |
CN109661389A (zh) * | 2016-08-23 | 2019-04-19 | 豪夫迈·罗氏有限公司 | 作为htra1抑制剂的新型二氟酮酰胺衍生物 |
EP3684374A4 (de) | 2017-09-21 | 2021-06-16 | Riboscience LLC | 4'-fluor-2'-methyl-substituierte nukleosidderivate als hemmer der hcv-rna-replikation |
CN109337537B (zh) * | 2018-09-26 | 2022-10-25 | 河北晨阳工贸集团有限公司 | 一种起重机专用单组分水性面漆及其制备方法 |
CN110668538B (zh) * | 2019-09-20 | 2021-10-22 | 济南大学 | 一种聚合氯化钛的制备方法 |
CN114057702B (zh) * | 2020-07-31 | 2022-09-30 | 四川大学 | 一种新型冠状病毒主蛋白酶的抑制剂及其制备方法和用途 |
CN115960088A (zh) * | 2020-07-31 | 2023-04-14 | 四川大学 | 一种新型冠状病毒主蛋白酶的抑制剂及其制备方法和用途 |
WO2023149981A1 (en) * | 2022-02-07 | 2023-08-10 | Purdue Research Foundation | Compounds for the treatment of sars |
CN114703003B (zh) * | 2022-04-14 | 2023-04-28 | 上海绿晟环保科技有限公司 | 一种负载碳量子点的纳米材料润滑添加剂及其制备方法 |
CN115417790A (zh) * | 2022-10-09 | 2022-12-02 | 山东大学 | 一类新型偶氮类发泡剂及合成方法 |
Family Cites Families (163)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3719667A (en) | 1970-08-24 | 1973-03-06 | Lilly Co Eli | Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters |
US3840556A (en) | 1971-05-28 | 1974-10-08 | Lilly Co Eli | Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby |
DE3226768A1 (de) | 1981-11-05 | 1983-05-26 | Hoechst Ag, 6230 Frankfurt | Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung |
DE3211676A1 (de) | 1982-03-30 | 1983-10-06 | Hoechst Ag | Neue derivate von cycloalka (c) pyrrol-carbonsaeuren, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie neue cycloalka (c) pyrrol-carbonsaeuren als zwischenstufen und verfahren zu deren herstellung |
US4499082A (en) | 1983-12-05 | 1985-02-12 | E. I. Du Pont De Nemours And Company | α-Aminoboronic acid peptides |
FR2570695A1 (fr) * | 1984-09-27 | 1986-03-28 | Synthelabo | Diphenylazomethines a chaine ramifiee ou cyclique, leur preparation et leur application en therapeutique |
FR2575753B1 (fr) | 1985-01-07 | 1987-02-20 | Adir | Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
US5496927A (en) | 1985-02-04 | 1996-03-05 | Merrell Pharmaceuticals Inc. | Peptidase inhibitors |
EP0204571B1 (de) * | 1985-06-07 | 1992-01-22 | Ici Americas Inc. | Selektionierte Difluorverbindungen |
US4835168A (en) | 1985-12-16 | 1989-05-30 | Eli Lilly And Company | Thiadiazole antiviral agents |
US5231084A (en) | 1986-03-27 | 1993-07-27 | Hoechst Aktiengesellschaft | Compounds having a cognition adjuvant action, agents containing them, and the use thereof for the treatment and prophylaxis of cognitive dysfuncitons |
US5736520A (en) | 1988-10-07 | 1998-04-07 | Merrell Pharmaceuticals Inc. | Peptidase inhibitors |
NZ235155A (en) | 1989-09-11 | 1993-04-28 | Merrell Dow Pharma | Peptidase substrates in which the carboxy terminal group has been replaced by a tricarbonyl radical |
US5371072A (en) * | 1992-10-16 | 1994-12-06 | Corvas International, Inc. | Asp-Pro-Arg α-keto-amide enzyme inhibitors |
ES2150933T3 (es) | 1992-12-22 | 2000-12-16 | Lilly Co Eli | Inhibidores de la proteasa vih utiles para el tratamiento del sida. |
JP2637847B2 (ja) | 1992-12-29 | 1997-08-06 | アボツト・ラボラトリーズ | レトロウィルス蛋白分解酵素を阻害する化合物 |
US5384410A (en) | 1993-03-24 | 1995-01-24 | The Du Pont Merck Pharmaceutical Company | Removal of boronic acid protecting groups by transesterification |
US5656600A (en) | 1993-03-25 | 1997-08-12 | Corvas International, Inc. | α-ketoamide derivatives as inhibitors of thrombosis |
US5672582A (en) | 1993-04-30 | 1997-09-30 | Merck & Co., Inc. | Thrombin inhibitors |
IL110752A (en) | 1993-09-13 | 2000-07-26 | Abbott Lab | Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor |
US5559158A (en) | 1993-10-01 | 1996-09-24 | Abbott Laboratories | Pharmaceutical composition |
US5468858A (en) | 1993-10-28 | 1995-11-21 | The Board Of Regents Of Oklahoma State University Physical Sciences | N-alkyl and n-acyl derivatives of 3,7-diazabicyclo-[3.3.1]nonanes and selected salts thereof as multi-class antiarrhythmic agents |
IL111991A (en) | 1994-01-28 | 2000-07-26 | Abbott Lab | Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent |
RU95104898A (ru) | 1994-03-31 | 1996-12-27 | Бристоль-Мейерз Сквибб Компани (US) | Имидазолсодержащие ингибиторы фарнезид-протеинтрансферазы, способ лечения связанных с ней заболеваний |
US6420522B1 (en) | 1995-06-05 | 2002-07-16 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
US5847135A (en) | 1994-06-17 | 1998-12-08 | Vertex Pharmaceuticals, Incorporated | Inhibitors of interleukin-1β converting enzyme |
US5716929A (en) | 1994-06-17 | 1998-02-10 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
US5756466A (en) | 1994-06-17 | 1998-05-26 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
US5861267A (en) | 1995-05-01 | 1999-01-19 | Vertex Pharmaceuticals Incorporated | Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity |
US6037157A (en) | 1995-06-29 | 2000-03-14 | Abbott Laboratories | Method for improving pharmacokinetics |
JPH09124691A (ja) * | 1995-08-25 | 1997-05-13 | Green Cross Corp:The | ペプチド化合物およびそれを含有する医薬組成物 |
JP2000500760A (ja) | 1995-11-23 | 2000-01-25 | メルク シヤープ エンド ドーム リミテツド | スピロピペリジン誘導体およびタキキニン拮抗薬としてのその使用 |
US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
US6054472A (en) | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
ZA972195B (en) | 1996-03-15 | 1998-09-14 | Du Pont Merck Pharma | Spirocycle integrin inhibitors |
TR199802136T2 (xx) | 1996-04-23 | 2001-06-21 | Vertex Pharmaceuticals Incorporated | �MPDH enzimi inhibit�rleri olarak �re t�revleri. |
US6127422A (en) | 1996-05-06 | 2000-10-03 | Eli Lilly And Company | Anti-viral method |
US5990276A (en) | 1996-05-10 | 1999-11-23 | Schering Corporation | Synthetic inhibitors of hepatitis C virus NS3 protease |
WO1997043310A1 (en) | 1996-05-10 | 1997-11-20 | Schering Corporation | Synthetic inhibitors of hepatitis c virus ns3 protease |
CN1218479A (zh) | 1996-05-17 | 1999-06-02 | 咨询卡有限公司 | 可固化的表面涂层组合物及其使用方法 |
EP0913389A4 (de) * | 1996-06-28 | 2000-02-02 | Nippon Chemiphar Co | Cyclopropylglycinderivate und agonisten des l-glutamatrezeptors vom typ der metabolitenregulation |
US6245919B1 (en) * | 1996-06-28 | 2001-06-12 | Haruhiko Shinozaki | Cyclopropylglycine derivatives and agonists for metabotronic L-glutamate receptors |
US6153579A (en) | 1996-09-12 | 2000-11-28 | Vertex Pharmaceuticals, Incorporated | Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex |
EP0929554B1 (de) | 1996-09-25 | 2006-03-15 | MERCK SHARP & DOHME LTD. | Spiro-azacyclische derivate, deren herstellung und verwendung als tachykinin-antagonisten |
JP2001502316A (ja) | 1996-10-08 | 2001-02-20 | コロラド ステート ユニバーシティ リサーチ ファンデーション | 触媒不斉エポキシ化 |
EA001915B1 (ru) * | 1996-10-18 | 2001-10-22 | Вертекс Фармасьютикалз Инкорпорейтед | Ингибиторы серин-протеаз, в частности ns3 протеазы вируса гепатита c (hvc) |
GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
DE19648011A1 (de) | 1996-11-20 | 1998-05-28 | Bayer Ag | Cyclische Imine |
AU6701598A (en) | 1997-03-14 | 1998-09-29 | Vertex Pharmaceuticals Incorporated | Inhibitors of impdh enzyme |
GB9707659D0 (en) | 1997-04-16 | 1997-06-04 | Peptide Therapeutics Ltd | Hepatitis C NS3 Protease inhibitors |
GB9708484D0 (en) | 1997-04-25 | 1997-06-18 | Merck Sharp & Dohme | Therapeutic agents |
GB9711114D0 (en) | 1997-05-29 | 1997-07-23 | Merck Sharp & Dohme | Therapeutic agents |
US6767991B1 (en) | 1997-08-11 | 2004-07-27 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C inhibitor peptides |
EP1012180B1 (de) | 1997-08-11 | 2004-12-01 | Boehringer Ingelheim (Canada) Ltd. | Peptidanaloga mit inhibitorischer wirkung auf hepatitis c |
ES2241157T3 (es) * | 1997-08-11 | 2005-10-16 | Boehringer Ingelheim (Canada) Ltd. | Peptidos inhibidores de la hepatitis c. |
US6183121B1 (en) | 1997-08-14 | 2001-02-06 | Vertex Pharmaceuticals Inc. | Hepatitis C virus helicase crystals and coordinates that define helicase binding pockets |
US20040058982A1 (en) | 1999-02-17 | 2004-03-25 | Bioavailability System, Llc | Pharmaceutical compositions |
US20020017295A1 (en) | 2000-07-07 | 2002-02-14 | Weers Jeffry G. | Phospholipid-based powders for inhalation |
US6211338B1 (en) | 1997-11-28 | 2001-04-03 | Schering Corporation | Single-chain recombinant complexes of hepatitis C virus NS3 protease and NS4A cofactor peptide |
JP4690545B2 (ja) | 1998-03-31 | 2011-06-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | セリンプロテアーゼ、特にc型肝炎ウイルスns3プロテアーゼの阻害因子 |
US6518305B1 (en) * | 1998-04-23 | 2003-02-11 | Abbott Laboratories | Five-membered carbocyclic and heterocyclic inhibitors of neuraminidases |
US6251583B1 (en) | 1998-04-27 | 2001-06-26 | Schering Corporation | Peptide substrates for HCV NS3 protease assays |
GB9812523D0 (en) | 1998-06-10 | 1998-08-05 | Angeletti P Ist Richerche Bio | Peptide inhibitors of hepatitis c virus ns3 protease |
AR022061A1 (es) * | 1998-08-10 | 2002-09-04 | Boehringer Ingelheim Ca Ltd | Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos. |
US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
DE19836514A1 (de) | 1998-08-12 | 2000-02-17 | Univ Stuttgart | Modifikation von Engineeringpolymeren mit N-basischen Gruppe und mit Ionenaustauschergruppen in der Seitenkette |
US6117639A (en) | 1998-08-31 | 2000-09-12 | Vertex Pharmaceuticals Incorporated | Fusion proteins, DNA molecules, vectors, and host cells useful for measuring protease activity |
US6025516A (en) | 1998-10-14 | 2000-02-15 | Chiragene, Inc. | Resolution of 2-hydroxy-3-amino-3-phenylpropionamide and its conversion to C-13 sidechain of taxanes |
EP1027885B1 (de) | 1999-02-09 | 2008-07-09 | Pfizer Products Inc. | Zusammensetzungen basischer Arzneistoffe mit verbesserter Bioverfügbarkeit |
US20020042046A1 (en) | 1999-02-25 | 2002-04-11 | Vertex Pharmaceuticals, Incorporated | Crystallizable compositions comprising a hepatitis C virus NS3 protease domain/NS4A complex |
EE200100492A (et) | 1999-03-19 | 2002-12-16 | Vertex Pharmaceuticals Incorporated | Ensüümi IMPDH inhibiitorid |
US6608027B1 (en) | 1999-04-06 | 2003-08-19 | Boehringer Ingelheim (Canada) Ltd | Macrocyclic peptides active against the hepatitis C virus |
US7122627B2 (en) | 1999-07-26 | 2006-10-17 | Bristol-Myers Squibb Company | Lactam inhibitors of Hepatitis C virus NS3 protease |
US20020183249A1 (en) | 1999-08-31 | 2002-12-05 | Taylor Neil R. | Method of identifying inhibitors of CDC25 |
AU2055301A (en) | 1999-12-03 | 2001-06-12 | Bristol-Myers Squibb Pharma Company | Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease |
US6365380B2 (en) * | 2000-02-23 | 2002-04-02 | Pcbu Services, Inc. | Method for stereoselectively inverting a chiral center of a chemical compound using an enzyme and a metal catalyst |
US6699855B2 (en) | 2000-02-29 | 2004-03-02 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus NS3 protease |
ES2240446T3 (es) | 2000-04-03 | 2005-10-16 | Vertex Pharma | Inhibidores de serina proteasas, particularmente la proteasa ns3 del virus de la hepatitis c. |
WO2001077113A2 (en) | 2000-04-05 | 2001-10-18 | Schering Corporation | Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties |
CN1935833A (zh) | 2000-04-19 | 2007-03-28 | 先灵公司 | 含有烷基和芳基丙氨酸p2部分的丙型肝炎病毒的大环ns3-丝氨酸蛋白酶抑制剂 |
AU2001267886A1 (en) | 2000-06-30 | 2002-01-14 | Seikagaku Corporation | Epoxycarboxylic acid amides, azides and amino alcohols and processes for preparation of alpha-keto amides by using them |
AR034127A1 (es) | 2000-07-21 | 2004-02-04 | Schering Corp | Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento |
US7244721B2 (en) | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
KR100939155B1 (ko) | 2000-07-21 | 2010-01-28 | 쉐링 코포레이션 | C형 간염 바이러스의 ns3-세린 프로테아제 억제제로서의신규한 펩티드 |
HUP0303358A3 (en) | 2000-07-21 | 2005-10-28 | Schering Corp | Novel peptides as ns3-serine protease inhibitors of hepatitis c virus and pharmaceutical compositions containing them |
AR029851A1 (es) | 2000-07-21 | 2003-07-16 | Dendreon Corp | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c |
JP2004504407A (ja) | 2000-07-21 | 2004-02-12 | コルバス・インターナショナル・インコーポレイテッド | C型肝炎ウイルスのns3−セリンプロテアーゼ阻害剤としての新規ペプチド |
US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
SV2003000617A (es) * | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
US6939692B2 (en) | 2000-09-12 | 2005-09-06 | Degussa Ag | Nucleotide sequences coding for the pknB gene |
US6846806B2 (en) | 2000-10-23 | 2005-01-25 | Bristol-Myers Squibb Company | Peptide inhibitors of Hepatitis C virus NS3 protein |
HUP0500456A3 (en) | 2000-11-20 | 2012-05-02 | Bristol Myers Squibb Co | Hepatitis c tripeptide inhibitors, pharmaceutical compositions comprising thereof and their use |
EP1343807B1 (de) | 2000-12-12 | 2009-04-29 | Schering Corporation | Diarylrest entfassende peptide als inhibitoren des ns-3 serinproteases von hepatitis c virus |
US6727366B2 (en) | 2000-12-13 | 2004-04-27 | Bristol-Myers Squibb Pharma Company | Imidazolidinones and their related derivatives as hepatitis C virus NS3 protease inhibitors |
US6653295B2 (en) | 2000-12-13 | 2003-11-25 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus NS3 protease |
SK286630B6 (sk) | 2001-01-22 | 2009-02-05 | Merck & Co., Inc. | Nukleozidové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie |
GB0102342D0 (en) | 2001-01-30 | 2001-03-14 | Smithkline Beecham Plc | Pharmaceutical formulation |
US20020187488A1 (en) | 2001-01-30 | 2002-12-12 | Chao Lin | Quantitative assay for nucleic acids |
ES2328466T3 (es) | 2001-03-27 | 2009-11-13 | Vertex Pharmaceuticals Incorporated | Composiciones y metodos utiles para la infeccion por hcv. |
GB0107924D0 (en) | 2001-03-29 | 2001-05-23 | Angeletti P Ist Richerche Bio | Inhibitor of hepatitis C virus NS3 protease |
CA2450545A1 (en) | 2001-07-03 | 2003-01-16 | Altana Pharma Ag | Process for the production of 3-phenylisoserine |
WO2003006490A1 (en) | 2001-07-11 | 2003-01-23 | Vertex Pharmaceuticals Incorporated | Bridged bicyclic serine protease inhibitors |
US7029561B2 (en) | 2001-07-25 | 2006-04-18 | The United States Of America As Represented By The Secretary Of Commerce | Fluidic temperature gradient focusing |
JP2003055389A (ja) | 2001-08-09 | 2003-02-26 | Univ Tokyo | 錯体及びそれを用いたエポキシドの製法 |
US6824769B2 (en) | 2001-08-28 | 2004-11-30 | Vertex Pharmaceuticals Incorporated | Optimal compositions and methods thereof for treating HCV infections |
CA2462163A1 (en) | 2001-10-24 | 2003-05-01 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system |
HUP0501067A2 (en) | 2001-11-14 | 2006-02-28 | Teva Pharma | Amorphous and crystalline forms of losartan potassium and process for their preparation |
CA2369711A1 (en) | 2002-01-30 | 2003-07-30 | Boehringer Ingelheim (Canada) Ltd. | Macrocyclic peptides active against the hepatitis c virus |
CA2369970A1 (en) | 2002-02-01 | 2003-08-01 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis c inhibitor tri-peptides |
US6642204B2 (en) | 2002-02-01 | 2003-11-04 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
US7091184B2 (en) | 2002-02-01 | 2006-08-15 | Boehringer Ingelheim International Gmbh | Hepatitis C inhibitor tri-peptides |
AR038375A1 (es) | 2002-02-01 | 2005-01-12 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo |
AU2003223602B8 (en) | 2002-04-11 | 2010-05-27 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis C virus NS3-NS4 protease |
MXPA05001298A (es) | 2002-08-01 | 2005-11-04 | Pharmasset Inc | Compuestos con el sistema biciclo[4.2.1] nonano para el tratamiento de infecciones por flaviviridae. |
US20050075279A1 (en) | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
CA2413705A1 (en) | 2002-12-06 | 2004-06-06 | Raul Altman | Use of meloxicam in combination with an antiplatelet agent for treatment of acute coronary syndrome and related conditions |
US7601709B2 (en) | 2003-02-07 | 2009-10-13 | Enanta Pharmaceuticals, Inc. | Macrocyclic hepatitis C serine protease inhibitors |
US7098231B2 (en) | 2003-01-22 | 2006-08-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US7223785B2 (en) | 2003-01-22 | 2007-05-29 | Boehringer Ingelheim International Gmbh | Viral polymerase inhibitors |
US20040180815A1 (en) | 2003-03-07 | 2004-09-16 | Suanne Nakajima | Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors |
JP2006517960A (ja) | 2003-02-18 | 2006-08-03 | ファイザー インコーポレイテッド | C型肝炎ウイルスの阻害剤、それを使用する組成物および治療法 |
EP1601685A1 (de) | 2003-03-05 | 2005-12-07 | Boehringer Ingelheim International GmbH | Hepatitis-c-inhibitierende verbindungen |
DE602004029866D1 (de) | 2003-03-05 | 2010-12-16 | Boehringer Ingelheim Pharma | Peptidanaloga mit inhibitorischer wirkung auf hepatitis c |
TW200510391A (en) | 2003-04-11 | 2005-03-16 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
CN100453553C (zh) | 2003-04-11 | 2009-01-21 | 沃泰克斯药物股份有限公司 | 丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂 |
DE602004010137T2 (de) | 2003-05-21 | 2008-09-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verbindungen als hepatitis c inhibitoren |
CN102020700A (zh) | 2003-07-18 | 2011-04-20 | 沃泰克斯药物股份有限公司 | 丝氨酸蛋白酶抑制剂、特别是hcv ns3-ns4a蛋白酶抑制剂 |
WO2005018330A1 (en) | 2003-08-18 | 2005-03-03 | Pharmasset, Inc. | Dosing regimen for flaviviridae therapy |
TW201127828A (en) | 2003-09-05 | 2011-08-16 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease |
US20050120398A1 (en) | 2003-09-12 | 2005-06-02 | Vertex Pharmaceuticals Incorporated | Animal model for HCV infection |
WO2005028502A1 (en) | 2003-09-18 | 2005-03-31 | Vertex Pharmaceuticals, Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
US6933760B2 (en) | 2003-09-19 | 2005-08-23 | Intel Corporation | Reference voltage generator for hysteresis circuit |
PE20050431A1 (es) | 2003-09-22 | 2005-07-19 | Boehringer Ingelheim Int | Peptidos macrociclicos activos contra el virus de la hepatitis c |
RU2006115558A (ru) | 2003-10-10 | 2007-11-20 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Ингибиторы сериновых протеаз, особенно hcv ns3-ns4a протеазы |
AR045870A1 (es) | 2003-10-11 | 2005-11-16 | Vertex Pharma | Terapia de combinacion para la infeccion de virus de hepatitis c |
WO2005043118A2 (en) | 2003-10-27 | 2005-05-12 | Vertex Pharmaceuticals Incorporated | Drug discovery method |
DE602004018363D1 (de) | 2003-10-27 | 2009-01-22 | Vertex Pharma | Kombinationen für die hcv-behandlung |
JP4890254B2 (ja) | 2003-10-27 | 2012-03-07 | バーテックス ファーマシューティカルズ インコーポレイテッド | Hcvns3−ns4aプロテアーゼ耐性突然変異体 |
CN1894211A (zh) | 2003-10-28 | 2007-01-10 | 沃泰克斯药物股份有限公司 | 借助费歇尔-芬克型合成和随后的酰化制备4,5-二烷基-3-酰基-吡咯-2-羧酸衍生物 |
US20050119318A1 (en) | 2003-10-31 | 2005-06-02 | Hudyma Thomas W. | Inhibitors of HCV replication |
US7132504B2 (en) | 2003-11-12 | 2006-11-07 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
CA2547787A1 (en) | 2003-12-01 | 2005-06-16 | Vertex Pharmaceuticals Incorporated | Compositions comprising fetal liver cells and methods useful for hcv infection |
ES2358333T3 (es) | 2004-01-21 | 2011-05-09 | Boehringer Ingelheim International Gmbh | Péptidos macrocíclicos con acción contra el virus de la hepatitis c. |
CA2554999A1 (en) | 2004-02-04 | 2005-08-25 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease |
UA86962C2 (en) | 2004-02-20 | 2009-06-10 | Бёрингер Ингельхайм Интернациональ Гмбх | Viral polymerase inhibitors |
US20050187192A1 (en) | 2004-02-20 | 2005-08-25 | Kucera Pharmaceutical Company | Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses |
ES2328589T3 (es) | 2004-02-27 | 2009-11-16 | Schering Corporation | Compuestos de la prolina 3,4(ciclopentil) fusionados como inhibidores de la proteasa serina ns3 del virus de la hepatitis c. |
CA2843066C (en) | 2004-03-12 | 2016-06-07 | Vertex Pharmaceuticals Incorporated | Processes and intermediates for the preparation of aspartic acetal caspase inhibitors |
WO2005107745A1 (en) | 2004-05-06 | 2005-11-17 | Schering Corporation | An inhibitor of hepatitis c |
WO2005123076A2 (en) | 2004-06-08 | 2005-12-29 | Vertex Pharmaceuticals, Inc. | Pharmaceutical compositions |
US7550559B2 (en) | 2004-08-27 | 2009-06-23 | Schering Corporation | Acylsulfonamide compounds as inhibitors of hepatitis C virus NS3 serine protease |
US7863274B2 (en) | 2005-07-29 | 2011-01-04 | Concert Pharmaceuticals Inc. | Deuterium enriched analogues of tadalafil as PDE5 inhibitors |
EP2402331A1 (de) | 2005-08-02 | 2012-01-04 | Vertex Pharmaceuticals Incorporated | Serinprotease-Hemmer |
PT1934179E (pt) | 2005-08-19 | 2010-07-12 | Vertex Pharma | PROCESSOS E INTERMEDIáRIOS |
AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
US7705138B2 (en) | 2005-11-11 | 2010-04-27 | Vertex Pharmaceuticals Incorporated | Hepatitis C virus variants |
EP1991229A2 (de) | 2006-02-27 | 2008-11-19 | Vertex Pharmaceuticals Incorporated | Kokristalle und pharmazeutische zusammensetzungen damit |
JP5313124B2 (ja) | 2006-03-16 | 2013-10-09 | バーテックス ファーマシューティカルズ インコーポレイテッド | 立体的化合物を製造するための方法および中間体 |
NZ571280A (en) | 2006-03-16 | 2011-10-28 | Vertex Pharma | Deuterated hepatitis C protease inhibitors |
AU2007226984B2 (en) | 2006-03-20 | 2013-02-21 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions |
AU2007226983A1 (en) | 2006-03-20 | 2007-09-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions |
CA2653625A1 (en) | 2006-05-31 | 2007-12-13 | Vertex Pharmaceuticals Incorporated | Controlled release formulations |
NZ579295A (en) | 2007-02-27 | 2012-03-30 | Vertex Pharma | Inhibitors of serine proteases |
-
2001
- 2001-08-30 SV SV2001000617A patent/SV2003000617A/es not_active Application Discontinuation
- 2001-08-31 AU AU2001288318A patent/AU2001288318B2/en not_active Ceased
- 2001-08-31 US US10/344,112 patent/US7820671B2/en not_active Expired - Fee Related
- 2001-08-31 CZ CZ2003595A patent/CZ2003595A3/cs unknown
- 2001-08-31 TW TW099107492A patent/TWI359145B/zh not_active IP Right Cessation
- 2001-08-31 NZ NZ541302A patent/NZ541302A/en not_active IP Right Cessation
- 2001-08-31 CN CN200910149349A patent/CN101696232A/zh active Pending
- 2001-08-31 SK SK249-2003A patent/SK2492003A3/sk unknown
- 2001-08-31 CN CN2011103464269A patent/CN102504014A/zh active Pending
- 2001-08-31 CA CA2419607A patent/CA2419607C/en not_active Expired - Fee Related
- 2001-08-31 PT PT01968040T patent/PT1320540E/pt unknown
- 2001-08-31 KR KR1020087025505A patent/KR20080104384A/ko not_active Application Discontinuation
- 2001-08-31 AT AT07012485T patent/ATE483686T1/de not_active IP Right Cessation
- 2001-08-31 IL IL15467101A patent/IL154671A0/xx unknown
- 2001-08-31 EP EP10185132.7A patent/EP2368877B1/de not_active Expired - Lifetime
- 2001-08-31 KR KR1020117015737A patent/KR20110088600A/ko not_active Application Discontinuation
- 2001-08-31 KR KR1020107007138A patent/KR20100042296A/ko active Application Filing
- 2001-08-31 DZ DZ013438A patent/DZ3438A1/fr active
- 2001-08-31 PL PL365836A patent/PL211019B1/pl unknown
- 2001-08-31 ES ES01968040T patent/ES2325481T3/es not_active Expired - Lifetime
- 2001-08-31 NZ NZ569670A patent/NZ569670A/en not_active IP Right Cessation
- 2001-08-31 CN CN2013100240570A patent/CN103232381A/zh active Pending
- 2001-08-31 BR BR0113666-6A patent/BR0113666A/pt not_active IP Right Cessation
- 2001-08-31 AR ARP010104168A patent/AR030591A1/es active IP Right Grant
- 2001-08-31 TW TW099107488A patent/TWI359144B/zh not_active IP Right Cessation
- 2001-08-31 SI SI200130924T patent/SI1320540T1/sl unknown
- 2001-08-31 HU HU0300855A patent/HUP0300855A3/hu unknown
- 2001-08-31 EP EP07111000A patent/EP1849797A3/de not_active Withdrawn
- 2001-08-31 ES ES10185132.7T patent/ES2489115T3/es not_active Expired - Lifetime
- 2001-08-31 ES ES07012483.9T patent/ES2450815T3/es not_active Expired - Lifetime
- 2001-08-31 DE DE60143233T patent/DE60143233D1/de not_active Expired - Lifetime
- 2001-08-31 EP EP20100185155 patent/EP2368901A1/de not_active Withdrawn
- 2001-08-31 EP EP10185722A patent/EP2371839A1/de not_active Withdrawn
- 2001-08-31 DK DK01968040.4T patent/DK1320540T5/da active
- 2001-08-31 KR KR1020077029814A patent/KR100945975B1/ko not_active IP Right Cessation
- 2001-08-31 UA UA2003021834A patent/UA81600C2/uk unknown
- 2001-08-31 TW TW099107489A patent/TWI378927B/zh not_active IP Right Cessation
- 2001-08-31 CN CNB018150551A patent/CN100522991C/zh not_active Expired - Fee Related
- 2001-08-31 DE DE60138717T patent/DE60138717D1/de not_active Expired - Lifetime
- 2001-08-31 EA EA200701869A patent/EA017556B1/ru not_active IP Right Cessation
- 2001-08-31 KR KR1020037002880A patent/KR100876472B1/ko not_active IP Right Cessation
- 2001-08-31 TW TW097127487A patent/TWI339661B/zh not_active IP Right Cessation
- 2001-08-31 EA EA200300318A patent/EA011547B1/ru not_active IP Right Cessation
- 2001-08-31 EP EP07012483.9A patent/EP1958956B1/de not_active Expired - Lifetime
- 2001-08-31 CN CN2009101474875A patent/CN101633636B/zh not_active Expired - Fee Related
- 2001-08-31 ES ES07012485T patent/ES2352804T3/es not_active Expired - Lifetime
- 2001-08-31 JP JP2002523884A patent/JP4689938B2/ja not_active Expired - Lifetime
- 2001-08-31 AU AU8831801A patent/AU8831801A/xx active Pending
- 2001-08-31 KR KR1020087025503A patent/KR100968295B1/ko not_active IP Right Cessation
- 2001-08-31 KR KR1020107007135A patent/KR20100043293A/ko not_active Application Discontinuation
- 2001-08-31 TW TW099107493A patent/TW201022244A/zh unknown
- 2001-08-31 WO PCT/US2001/026008 patent/WO2002018369A2/en active Application Filing
- 2001-08-31 MX MXPA03001780A patent/MXPA03001780A/es active IP Right Grant
- 2001-08-31 KR KR1020097022810A patent/KR20090120013A/ko not_active Application Discontinuation
- 2001-08-31 CN CN2006100803265A patent/CN1869061B/zh not_active Expired - Fee Related
- 2001-08-31 CN CN200910149350.3A patent/CN101693672B/zh not_active Expired - Fee Related
- 2001-08-31 EP EP07012485A patent/EP1878720B1/de not_active Expired - Lifetime
- 2001-08-31 EP EP01968040A patent/EP1320540B9/de not_active Expired - Lifetime
- 2001-08-31 PE PE2001000876A patent/PE20020474A1/es active IP Right Grant
- 2001-08-31 AT AT01968040T patent/ATE431358T1/de active
- 2001-08-31 KR KR1020087025506A patent/KR20080096718A/ko not_active Application Discontinuation
- 2001-08-31 DK DK07012485.4T patent/DK1878720T3/da active
- 2001-08-31 KR KR1020087025504A patent/KR20080104383A/ko not_active Application Discontinuation
- 2001-08-31 EP EP07012484A patent/EP1876173A1/de not_active Withdrawn
- 2001-08-31 CA CA2697205A patent/CA2697205C/en not_active Expired - Fee Related
- 2001-08-31 TW TW090121629A patent/TWI319763B/zh not_active IP Right Cessation
- 2001-08-31 DE DE20122915U patent/DE20122915U1/de not_active Expired - Lifetime
- 2001-08-31 UA UAA200710133A patent/UA99895C2/uk unknown
- 2001-08-31 EP EP10185148A patent/EP2368878A1/de not_active Withdrawn
-
2003
- 2003-02-25 HR HRP20030139AA patent/HRP20030139B8/hr not_active IP Right Cessation
- 2003-02-25 EC EC2003004493A patent/ECSP034493A/es unknown
- 2003-02-27 ZA ZA200301641A patent/ZA200301641B/en unknown
- 2003-02-27 NO NO20030928A patent/NO329929B1/no not_active IP Right Cessation
- 2003-02-27 IL IL154671A patent/IL154671A/en not_active IP Right Cessation
- 2003-11-19 HK HK12103079.4A patent/HK1163061A1/xx not_active IP Right Cessation
- 2003-11-19 HK HK03108422.8A patent/HK1057758A1/xx not_active IP Right Cessation
- 2003-11-19 HK HK08104142.1A patent/HK1114090A1/xx not_active IP Right Cessation
-
2007
- 2007-01-31 EC EC2007007217A patent/ECSP077217A/es unknown
- 2007-05-30 JP JP2007143124A patent/JP2007284444A/ja active Pending
- 2007-08-30 IL IL185644A patent/IL185644A0/en unknown
-
2008
- 2008-09-08 US US12/231,982 patent/US8252923B2/en not_active Expired - Fee Related
-
2009
- 2009-07-20 CY CY20091100765T patent/CY1109216T1/el unknown
-
2010
- 2010-01-18 NO NO20100093A patent/NO20100093L/no not_active Application Discontinuation
- 2010-04-07 CL CL2010000330A patent/CL2010000330A1/es unknown
- 2010-07-12 NO NO20100999A patent/NO330807B1/no not_active IP Right Cessation
- 2010-10-25 JP JP2010238165A patent/JP5269035B2/ja not_active Expired - Fee Related
-
2011
- 2011-10-24 IL IL215892A patent/IL215892A/en not_active IP Right Cessation
- 2011-10-24 IL IL215890A patent/IL215890A0/en unknown
- 2011-10-24 IL IL215891A patent/IL215891A/en not_active IP Right Cessation
- 2011-11-10 US US13/293,812 patent/US20120064034A1/en not_active Abandoned
-
2012
- 2012-03-19 CY CY2012007C patent/CY2012007I1/el unknown
- 2012-03-19 DE DE201212000015 patent/DE122012000015I1/de active Pending
- 2012-03-19 LU LU91960C patent/LU91960I2/fr unknown
- 2012-04-03 NO NO2012006C patent/NO2012006I1/no unknown
- 2012-05-28 JP JP2012120678A patent/JP2012197289A/ja active Pending
- 2012-07-03 US US13/541,436 patent/US8529882B2/en not_active Expired - Fee Related
-
2014
- 2014-06-17 US US14/306,778 patent/US20140294763A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE431358T1 (de) | Peptidomimetika als protease inhibitoren | |
ATE437862T1 (de) | Pyrimidin-5-onderivate als ldl-pla2 inhibitoren | |
CY2015028I2 (el) | Ενας αναστολεας ν-ακυλοσφιγγοσινο γλυκοζυλοτρανσφερασης | |
DE60134094D1 (de) | C7-taxanester als antitumormittel | |
ATE484496T1 (de) | Metalloproteinaseinhibitoren | |
EE200300439A (et) | Metalloproteinaasi inhibiitorid | |
DK1294714T3 (da) | Trombinreceptorantagonister | |
DE60234125D1 (de) | E inhibitoren | |
DK1383731T3 (da) | Biarylforbindelser som serinproteaseinhibitorer | |
ATE534622T1 (de) | Aspartylprotease-inhibitoren | |
NO20004696D0 (no) | Kinoloner som serinproteaseinhibitorer | |
EE200300452A (et) | Metalloproteinaasi inhibiitorid | |
DK1272488T3 (da) | Tri-aryl-substitueret ethan-PDE4-inhibitorer | |
ATE428420T1 (de) | Substituierte 8-arylchinoline als phosphodiesterase-4-hemmer | |
ATE429431T1 (de) | 2-amino-benzoxazol-suphonamide als breitspektrum- hiv-protease-inhibitoren | |
NO20025786L (no) | Protaseinhibitorer | |
NO20025005D0 (no) | Proteaseinhibitorer | |
NO20032328L (no) | Proteaseinhibitorer | |
DE60118941D1 (de) | Pyrrolidin-2-carbonsäure-hydrazid-derivate als metalloprotease-inhibitoren | |
DK1130214T3 (da) | Korrosionsinhibitorer | |
DE60132468D1 (de) | Alen-lanosterol zyklase inhibitoren | |
AR028075A1 (es) | Inhibidores de la peptido-desformilasa | |
DE60204623D1 (de) | Inhibitor-Schalteranordnung | |
ATE270267T1 (de) | Scyphostatin-analoga als smase-inhibitoren | |
DE602004014762D1 (de) | Proteasehemmer |